Correlation between Osteoprotegerin Serum Level and Coronary Calcification Using Coronary Artery Calcium Score in Patient with Moderate–Severe Cardiovascular Risk Factor

Abstract

Coronary artery calcification is a part of atherosclerosis process associated with coronary heart disease. Recently, coronary artery calcification assessment using computed tomography (CT) is still the best noninvasive imaging with high sensitivity and specificity. Osteoprotegerin (OPG) is one of vascular calcification marker that through its role to bind receptor activator of nuclear factor-κβ ligand and inhibit osteoclastogenesis is suspected of playing a role for coronary calcification in atherosclerosis process. The objective of this study was to prove a positive correlation between OPG serum level and coronary calcification using coronary artery calcium (CAC) score in patient with moderate–severe cardiovascular (CV) risk factor. This is a cross-sectional study with purposive sampling technique. Thirty-three subjects participate in this research and each subject underwent a multislice computed tomography (MSCT) examination to assess coronary calcification and their blood samples were collected for OPG measurement. This study is analyzed with Spearman's correlation test. The mean of OPG serum level in this study was 5.89 ± 2.1 pmol/L for moderate-risk Framingham risk score (FRS) and the mean of OPG serum level for high-risk FRS was 7.27 ± 3.4. There was a positive, moderate, and significant correlation between OPG serum level and coronary calcification using CAC score in patient with moderate–severe CV risk factor (r = 0.694; p < 0.001).

Keywords

coronary artery - calcium score - osteoprotegerin - Framingham risk score - moderate–severe cardiovascular risk factor - atherosclerosis - coronary calcification

• References

• 1 Laslett LJ, Alagona Jr P, Clark III BA. , et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 2012; 60 (25, Suppl): S1-S49
• 2 Perk J, De Backer G, Gohlke H. , et al; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33 (13) 1635-1701
• 3 Kohli P, Whelton SP, Hsu S. , et al. Clinician's guide to the updated ABCs of cardiovascular disease prevention. J Am Heart Assoc 2014; 3 (05) e001098
• 4 Sharma RK, Sharma RK, Voelker DJ. , et al. Cardiac risk stratification: role of the coronary calcium score. Vasc Health Risk Manag 2010; 6: 603-611
• 5 Greenland P. , et al. ACCF/AHA Clinical Expert Consensus Document on Coronary Artery Calcium Score by Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain. Circulation 2007; 115: 402-426
• 6 Budoff MJ, Gul KM. Expert review on coronary calcium. Vasc Health Risk Manag 2008; 4 (02) 315-324
• 7 Gerber TC. Diagnostic and Prognostic Implications of Coronary Artery Calcification Detected by Computed Tomography. 2014. Available at: www.uptodate.com . Accessed on January 13, 2017
• 8 Mollet NR, Cademartiri F, de feyter PJ. Non-invasive multislice CT coronary imaging. Heart 2005; 91: 401-407
• 9 Romanens MJ, Bergerb DC, Battegay EJ. Predictive value of clinical risk assessment tools and guidelines for 10-year coronary heart disease risk in practice-based primary care. Kardiovaskuläre Medizin 2005; 8: 180-186
• 10 Madhavan MV, Tarigopula M, Mintz GS, Maehara A, Stone GW, Généreux P. Coronary artery calcification: pathogenesis and prognostic implications. J Am Coll Cardiol 2014; 63 (17) 1703-1714
• 11 Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010; 55 (19) 2049-2061
• 12 Mangan SH, Van Campenhout A, Rush C, Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-α associated with induction of angiopoietin-2. Cardiovasc Res 2007; 76 (03) 494-505
• 13 Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab 2003; 88 (11) 5361-5365
• 14 Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 2003; 228: 826-833
• 15 Anand DV, Lahiri A, Lim E. , et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47 (09) DOI: 10.1016/j.jacc.2005.12.054.
• 16 Pérez de Ciriza C, Moreno M, Restituto P. , et al. Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification. Clin Biochem 2014; 47 (18) 272-278